Saturday, 01 Oct, 2022

Health

Lung cancer therapy is 'milestone'

Health Desk |
Update: 2015-05-30 02:28:00
Lung cancer therapy is 'milestone'

DHAKA: A lung cancer therapy can more than double life expectancy in some patients, a "milestone" trial shows.

Nivolumab stops cancerous cells hiding from the body's own defences, leaving the cancer vulnerable to attack, reports BBC.

The results from 582 people, presented at the American Society of Clinical Oncology, were described as "giving real hope to patients".

Lung cancer is the most deadly type of cancer, killing nearly 1.6 million people every year.

It is hard to treat as it is often diagnosed late and many people with smoking-related diseases are unsuitable for surgery.

Natural defences

Your immune system is trained to fight infection, but it also attacks parts of the body if they malfunction - such as in cancers.

However, tumours have a few tricks up their sleeve in order to survive.

They can produce a protein called PD-L1 which switches off any part of the immune system that tries to attack them.

Nivolumab is one of a suite of drugs called "checkpoint inhibitors" being developed by pharmaceutical companies.

They stop cancers turning off the immune system so the body can keep on attacking the tumour.

The trial, conducted in Europe and the US, was on patients who had advanced lung cancer and who had already tried other treatments.

People on standard therapy lived for another 9.4 months at this stage, but those taking Nivolumab lived for 12.2 months on average.

However, some patients did spectacularly well. Those whose tumours were producing high levels of PD-L1 lived for another 19.4 months.

'Milestone'

The data was presented by the pharmaceutical company Bristol-Myers Squibb.

Lead researcher Dr Luis Paz-Ares, from the Hospital Universitario Doce de Octubre in Madrid, Spain, said: "[The results] mark a milestone in the development of new treatment options for lung cancer."

"Nivolumab is the first PD-1 inhibitor to show a significant improvement in overall survival in a phase III trial in non-squamous non-small cell lung cancer."

Many other companies are assessing similar drugs.

Dr Martin Forster, from the University College London Cancer Institute, is trialling some of them.

He told the BBC News website: "It's really exciting, I think these drugs will be a paradigm shift in how we treat lung cancer."

He said that after chemotherapy failed, current survival rates were "dire".

"But in those that respond [to immunotherapy] there seems to be very prolonged disease control, I think it's a huge shift in lung cancer and for patients it's going to be dramatic," he said.

BDST: 1230 HRS, MAY 30, 2015
RS

All rights reserved. Sale, redistribution or reproduction of information/photos/illustrations/video/audio contents on this website in any form without prior permission from banglanews24.com are strictly prohibited and liable to legal action.